Daljit Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daljit Kaur has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
Gita Negi
16 shared publicationsAshish Jain
Department of Transfusion Medicine All India Institute of Medical Sciences—Rishikesh Rishikesh India
9 shared publications- Ashish Jain
Department of Transfusion Medicine All India Institute of Medical Sciences Rishikesh Rishikesh India
7 shared publications Dixa Kumari
Department of Transfusion Medicine All India Institute of Medical Sciences—Rishikesh Rishikesh India
4 shared publications- Lovenish Bains
Department Of Surgery, Maulana Azad Medical College, New Delhi, India
4 shared publications Suhasini Sil
Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India
4 shared publications
Latest Publications
- 6 November 2026
- Published by Elsevier
Contributors
- 6 November 2026
- Published by Elsevier
- p. 191-197
Patient blood management in hematological patient populations
- 6 November 2026
- Published by Elsevier
- p. 191-197
Patient blood management in hematological patient populations
- 6 November 2026
- Published by Elsevier
- p. 161-166
Patient blood management in obstetrics
- 22 January 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (4) , 377-385
A quasi‐experimental study evaluating the efficacy of crossmatch‐matched platelet transfusions in hemato‐oncology patients with suspected alloimmune platelet refractoriness: A single‐centre experience
Background: Platelet transfusion is essential in managing thrombocytopenia in hemato‐oncology patients. This study aimed to determine the prevalence of platelet refractoriness (PR) and to evaluate the efficacy of crossmatch‐compatible single‐donor platelet (SDP) transfusions in patients with suspected platelet refractoriness. Materials and Methods: A two‐year quasi‐experimental study comprised adult and paediatric hemato‐oncology patients with two consecutive low corrected count increment (CCI) responses (p = 0.001) and PPR (44.8% vs. 28.7%, p < 0.001). Crossmatching demonstrated high sensitivity (84.8%) and NPV (86.4%) for detecting inadequate responses. Multivariate analysis identified platelet compatibility and age as significant predictors of transfusion efficacy. Conclusion: Crossmatch‐compatible platelet transfusions significantly improve post‐transfusion CCI and PPR in alloimmunised hemato‐oncology patients. Crossmatch compatibility and patient age were identified as two independent predictors of adequate early platelet transfusion response (1‐h CCI, PPR and platelet increment).
- 22 January 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (4) , 377-385
A quasi‐experimental study evaluating the efficacy of crossmatch‐matched platelet transfusions in hemato‐oncology patients with suspected alloimmune platelet refractoriness: A single‐centre experience
Background: Platelet transfusion is essential in managing thrombocytopenia in hemato‐oncology patients. This study aimed to determine the prevalence of platelet refractoriness (PR) and to evaluate the efficacy of crossmatch‐compatible single‐donor platelet (SDP) transfusions in patients with suspected platelet refractoriness. Materials and Methods: A two‐year quasi‐experimental study comprised adult and paediatric hemato‐oncology patients with two consecutive low corrected count increment (CCI) responses (p = 0.001) and PPR (44.8% vs. 28.7%, p < 0.001). Crossmatching demonstrated high sensitivity (84.8%) and NPV (86.4%) for detecting inadequate responses. Multivariate analysis identified platelet compatibility and age as significant predictors of transfusion efficacy. Conclusion: Crossmatch‐compatible platelet transfusions significantly improve post‐transfusion CCI and PPR in alloimmunised hemato‐oncology patients. Crossmatch compatibility and patient age were identified as two independent predictors of adequate early platelet transfusion response (1‐h CCI, PPR and platelet increment).
- 27 September 2025
- Published by Wiley in Transfusion Medicine
- Vol. 36 (2) , 165-174
Implementation of a patient blood management programme for platelet therapy among haemato‐oncology patients—A quasi‐experimental study
Background: The paucity of data pertaining to the implementation of the patient blood management (PBM) programme for platelet transfusion for improved patient outcomes with minimal risks motivated this study. The study aimed to implement an effective PBM programme for platelet transfusion therapy among haemato‐oncology patients evaluating transfusion appropriateness and educational intervention for dedicated platelet transfusion practitioners (PtP). Study Designs and Methods: A quasi‐experimental study was conducted for 1 year after Institutional ethics committee (IEC) (as shown in Annexure ) which included pre‐intervention, intervention and post‐intervention phases for four months each. The study involved platelet auditing, online survey questionnaires, educational intervention for the platelet transfusion practitioners (PtP) and feedback for user satisfaction. Results: The platelet audit showed statistically significant improvement (chi‐square test, p < 0.05) in transfusion appropriateness, completeness of the forms filled, number of single donor apheresis procedures, ABO compatible transfusions and thereby reduction in platelet refractory cases during the post‐intervention phase compared to the pre‐intervention. The online survey showed improvement in self perceived knowledge and practice for all the stakeholders during the post‐intervention period. Conclusion: The introduction of platelet transfusion practitioners and the educational sessions they underwent, had a significant impact in achieving transfusion appropriateness for platelet therapy and they gained the ability to prioritise medical emergencies, optimise platelet inventory management and minimise wastage. Educational interventions have enhanced practitioners knowledge and sensitised them to adhere to standard evidence‐based platelet transfusion guidelines.
- 27 September 2025
- Published by Wiley in Transfusion Medicine
- Vol. 36 (2) , 165-174
Implementation of a patient blood management programme for platelet therapy among haemato‐oncology patients—A quasi‐experimental study
Background: The paucity of data pertaining to the implementation of the patient blood management (PBM) programme for platelet transfusion for improved patient outcomes with minimal risks motivated this study. The study aimed to implement an effective PBM programme for platelet transfusion therapy among haemato‐oncology patients evaluating transfusion appropriateness and educational intervention for dedicated platelet transfusion practitioners (PtP). Study Designs and Methods: A quasi‐experimental study was conducted for 1 year after Institutional ethics committee (IEC) (as shown in Annexure ) which included pre‐intervention, intervention and post‐intervention phases for four months each. The study involved platelet auditing, online survey questionnaires, educational intervention for the platelet transfusion practitioners (PtP) and feedback for user satisfaction. Results: The platelet audit showed statistically significant improvement (chi‐square test, p < 0.05) in transfusion appropriateness, completeness of the forms filled, number of single donor apheresis procedures, ABO compatible transfusions and thereby reduction in platelet refractory cases during the post‐intervention phase compared to the pre‐intervention. The online survey showed improvement in self perceived knowledge and practice for all the stakeholders during the post‐intervention period. Conclusion: The introduction of platelet transfusion practitioners and the educational sessions they underwent, had a significant impact in achieving transfusion appropriateness for platelet therapy and they gained the ability to prioritise medical emergencies, optimise platelet inventory management and minimise wastage. Educational interventions have enhanced practitioners knowledge and sensitised them to adhere to standard evidence‐based platelet transfusion guidelines.
- 8 September 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (4) , 341-349
Cryoprecipitate utilization review in light of recent guidelines: a single-center prospective analysis of haemato-oncology patients
- 8 September 2025
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (4) , 341-349
Cryoprecipitate utilization review in light of recent guidelines: a single-center prospective analysis of haemato-oncology patients
- 21 November 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 112-117
Potential advantage of therapeutic plasma exchange over intravenous immunoglobulin in children with axonal variant of Guillain-Barré syndrome: A report of six paediatric cases
- 21 November 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 112-117
Potential advantage of therapeutic plasma exchange over intravenous immunoglobulin in children with axonal variant of Guillain-Barré syndrome: A report of six paediatric cases
- Open Access
- 22 August 2024
- Published by Medknow in Asian Journal of Transfusion Science
- Vol. 20 (2) , 439-443
Near miss event: Sentinel to identifying catastrophic errors in transfusion chain
Although undesirable, near-miss events bring to light those previously overlooked areas and aid in training for strengthening the weaker “error-generating” links in the transfusion chain. These events may occur at the very first interaction with the patient at the hospital registration desk. Here, we present a case of a near-miss event, where an ABO-incompatible transfusion was averted, involving a patient misidentification error at the hospital registration desk, because of checks in the blood center information software.
- 22 August 2024
- Published by Medknow in Asian Journal of Transfusion Science
- Vol. 20 (2) , 439-443
Open AccessNear miss event: Sentinel to identifying catastrophic errors in transfusion chain
Although undesirable, near-miss events bring to light those previously overlooked areas and aid in training for strengthening the weaker “error-generating” links in the transfusion chain. These events may occur at the very first interaction with the patient at the hospital registration desk. Here, we present a case of a near-miss event, where an ABO-incompatible transfusion was averted, involving a patient misidentification error at the hospital registration desk, because of checks in the blood center information software.
- 17 June 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 127-136
Insight Into Aetiology and Severity of Hemolysis Associated with Immunoproteins on Red Cell Surface in Direct Antiglobulin Test Positive Auto-immune Hemolytic Anemia
The study aimed to find out the correlation of positive direct antiglobulin test (DAT) with features of autoimmune hemolysis in patients presenting to a tertiary care center in Northern India. Patient history, lab findings, and immune-hematological findings which can influence the management of patients with auto-immune hemolytic anemia were studied. DAT helps to differentiate immune hemolysis from non-immune hemolysis in patients with hemolytic anemia. A prospective study over 18 months was performed on DAT-positive samples of patients showing features of auto-immune hemolysis. The laboratory markers of hemolysis were correlated with immune-hematological studies like elution-adsorption, antibody specificity, and titer. Out of 1371 requests received for Immuno-hematological workup of patients with hemolysis, 92 (6.71%) met the inclusion criteria. Thirty (32.6%) patients were diagnosed with primary (Idiopathic) Auto-immune Hemolytic Anemia (AIHA), and the remaining 62(67.3%) patients had secondary AIHA. The gender distribution in primary AIHA was male: female as 1:2.7, while in secondary AIHA it was observed as male: female to be 1:1.3.The median age for primary AIHA was found to be 23.7 years (range 1 year to 48 years), and for secondary AIHA it was found to be 44.6 years (range 2 to 85 years). Of all AIHA patients tested, 85.8% showed the presence of warm autoantibodies in their sera while 7.6% had mixed-type AIHA and the remaining 6.5% had cold autoantibodies. The study highlights a strong association between higher strength of DAT positivity, multiple antibodies/immunoglobulins with complements coating red cells, and a higher titer of IgG and IgG1 & IgG3 subclass with the severity of hemolysis.
- 17 June 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 127-136
Insight Into Aetiology and Severity of Hemolysis Associated with Immunoproteins on Red Cell Surface in Direct Antiglobulin Test Positive Auto-immune Hemolytic Anemia
The study aimed to find out the correlation of positive direct antiglobulin test (DAT) with features of autoimmune hemolysis in patients presenting to a tertiary care center in Northern India. Patient history, lab findings, and immune-hematological findings which can influence the management of patients with auto-immune hemolytic anemia were studied. DAT helps to differentiate immune hemolysis from non-immune hemolysis in patients with hemolytic anemia. A prospective study over 18 months was performed on DAT-positive samples of patients showing features of auto-immune hemolysis. The laboratory markers of hemolysis were correlated with immune-hematological studies like elution-adsorption, antibody specificity, and titer. Out of 1371 requests received for Immuno-hematological workup of patients with hemolysis, 92 (6.71%) met the inclusion criteria. Thirty (32.6%) patients were diagnosed with primary (Idiopathic) Auto-immune Hemolytic Anemia (AIHA), and the remaining 62(67.3%) patients had secondary AIHA. The gender distribution in primary AIHA was male: female as 1:2.7, while in secondary AIHA it was observed as male: female to be 1:1.3.The median age for primary AIHA was found to be 23.7 years (range 1 year to 48 years), and for secondary AIHA it was found to be 44.6 years (range 2 to 85 years). Of all AIHA patients tested, 85.8% showed the presence of warm autoantibodies in their sera while 7.6% had mixed-type AIHA and the remaining 6.5% had cold autoantibodies. The study highlights a strong association between higher strength of DAT positivity, multiple antibodies/immunoglobulins with complements coating red cells, and a higher titer of IgG and IgG1 & IgG3 subclass with the severity of hemolysis.